Anthony Bourdain, Kate Spade, and the Growing #DestigmatizeDepression Movement
Idaho boy diagnosed with plague
Researchers discover link between religion and long life
Relay For Life of Lyon County reaches milestone year
Crow Tests Positive for West Nile Virus
Major study finds many breast cancer patients can skip chemotherapy
08 June 2018, 10:45 | Melissa Porter
Personalised medicine 'transforms' survival chances in incurable cancer
Findings of the past have indicated that women who met these criteria and scored below ten on the index test could safely skip chemotherapy without raising their rate of recurrence, however, those above 25 would nearly always be advised to use chemotherapy as a necessary treatment to lower risk of recurrence.
Dr Epstein, a clinical oncologist at Memorial Sloan Kettering Cancer Centre in NY, said the two studies show "the anti-inflammatory benefits of a relatively cheap, well-tolerated supplement".
In a new analysis, researchers examined 9,717 women between the ages of 18 and 75 with early-stage breast cancer that had not spread to lymph nodes. He said "Oncologists have been waiting for these results, it will affect practice on Monday morning".
Although the new findings are extremely promising for women who have early-stage breast cancer, the conclusions may not apply to those who have larger tumors or those battling cancer that has spread throughout the body.
For example, another study at the conference found that Merck's immunotherapy drug Keytruda worked better than chemo as initial treatment for most people with the most common type of lung cancer, and with far fewer side effects. "This life-changing breakthrough is absolutely wonderful news as it could liberate thousands of women from the agony of chemotherapy".
Lastly, these cancer diagnoses must land between 11 and 25 on the Oncotype DX Breast Recurrence Score test. All had surgery and hormone treatment, and half got chemo.
"The study should have a huge impact on doctors and patients - its findings will greatly expand the number of patients who can forgo chemotherapy without compromising their outcomes", said Kathy Albain, chair of oncology research at Loyola University School of Medicine, in Chicago, USA, and co-author of the study.
However an estimated 25% of patients stop within two years because they can not endure the side effects, lead author Dr Sherry Shen, of the New York Presbyterian Hospital, said.
The new effects are around the 67 percent of women at intermediate risk. The money was used to pay for the gene test, which costs more than $4,000 per person. Similar evaluations like one called MammaPrint are also widely used. Many women think "if I don't get chemotherapy I'm going to die, and if I get chemo I'm going to be cured", but the results show there's a sliding scale of benefit and sometimes none, he said. "Towards the end, my eyes would water", she said.
10 decades back in Montefiore and has been assigned to the team awarded chemo.
"I was a little relieved". "The remedies" were not agreeable", she concedes. Her hair fell out, she developed an infection and was hospitalized for a low white blood count, "but it was over fairly quickly and I'm really glad I had it". "I'm a firm believer in medical research".
Liverpool Reach £52.8m Agreement for Nabil Fekir
Nabil Fekir is to undergo a medical with Liverpool on Friday after the Reds thrashed out a fee with Lyon for his services. Fekir has also drawn interest from Chelsea and Bayern Munich, but Liverpool have been aggressive in chasing his signature.
A long-shot candidate but a second-place finisher
Ed Royce and Darrell Issa , and the district where Republican Dana Rohrabacher was facing challenges from the left and the right. Democrats have recruited candidates to run in state districts where Republican incumbents haven't faced challengers in years.